Find Funding Opportunities

This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

Many avenues of research are focused on improving our understanding of Lewy body dementia (LBD), including the disease's underlying biology and genetic risk factors. Environmental risk factors are also considered but are understudied. This Notice of Funding Opportunity (NOFO) is to support research that establishes causal links between a range of environmental factors and Lewy body formation.  These factors include exposures to environmental toxicants, light and noise, climate, and other external exposures.  This NOFO will support mechanistic, translational, and human subject studies to understand the relationship between environmental factors and LBD. It is expected that these studies will identify environmental risk factors related to the cause of LBD and its progression and their clinical relevance. Ultimately, these studies on LBD should accelerate mechanism-focused research to identify relevant pathways with potential to lead towards better and novel therapeutic interventions and quality of life. 

This initiative will solicit applications that propose the development and early stage validation of next generation humanized small animal models and/or human cellular microphysiological systems that improve the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression.

Reissue of RFA-NS-19-038. This Notice of Funding Opportunity (NOFO) invites applications to support the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders.

This Notice of Funding Opportunity (NOFO) invites applications for basic research to inform toxicology of chemical warfare agents and select toxic industrial chemicals and materials that have primary or secondary effects on the nervous system. These chemical threats are toxic compounds that have been identified by the United States Government (USG) as Chemicals of Concern (CoC) that could be deliberately or accidentally released into the civilian population. Research supported by this NOFO is expected to generate results that further elucidate mechanism(s) of toxicity of these agents and potential new targets for development of therapeutic/medial countermeasures that are effective in civilian mass exposure situations.  

The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies

The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies

Applications to this NOFO will propose research to establish clinical trial readiness for community-driven interventions to understand and develop solutions addressing barriers to equity in ADRD outcomes among populations defined by the NIH to experience health disparities and communities that intersect with them. Applications should consider the social, ethical, and behavioral implications (SEBI) related to assessing risk for, identification of, or treatment of ADRD among underserved and marginalized populations and how these factors may relate to existing or potential barriers to achieving equity and impact future clinical trials.

This Notice of Funding Opportunity (NOFO) invites new applications for Centers for Collaborative Research in Fragile X andFMR1-Associated Conditions (hereafter termed "Fragile X Centers"). Despite many remarkable advances in fundamental knowledge about FMR1-associated conditions, gaps in knowledge remain about the processes that drive the variability in clinical features (phenotypic heterogeneity) among affected individuals. In this round of competition, therefore, all centers will be required to identify an overarching theme directed at broadening our understanding of factors underlying the phenotypic heterogeneity and/or variability in response to interventions seen in one or more FMR1 associated conditions. Successful Fragile X Centers will be composed of multidisciplinary teams of basic, translational, clinical, and/or data science investigators applying precision medicine approaches (seeking to understand which mechanisms and interventions are most applicable to specific individuals or groups) to address the center's proposed overarching theme. This NOFO includes specific requirements about inclusion of research on human subjects or human phenotypic data; diversity of participants or materials being studied; the types of allowable clinical trials; and involvement of early-stage investigators. Applications that do not adhere to these requirements will be considered nonresponsive to this NOFO and will be withdrawn. In addition, this NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.Applicants are strongly encouraged to read the NOFO instructions carefully and view the availablePEDP guidance material.

Advances in structural biology have enabled the characterization of large protein assemblies that are linked to AD/ADRD pathology. However, most structural biology approaches require purified samples from cells and tissues or use recombinant bacterial proteins. The derived structures using ex-vivo material may not report the diversity of physiologically relevant species because reconstruction relies on class averaging that is biased towards dominant conformations that survive methodological processing. Recent developments in structural biology offer the possibility of in situ characterization of specific macromolecular assemblies. Structural information of protein assemblies and aggregates in their native cellular and tissue environments could facilitate rational structure-based ligand development. Currently, PET ligands that specifically identify and monitor the accumulation of aggregated and misfolded proteins in AD/ADRD patients are lacking.